Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

The current pain caused by the high cost of the GLP-1 agonist anti-obesity drugs will pass. Prachi Patkee and other analysts ...

Nearly three quarters of U.S. adults are overweight or obese, according to a sweeping new study. The findings have ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

"For healthcare providers, these findings suggest that anti-obesity medications may offer dual benefits," one doctor reports ...